How to Treat Hypertension in the Post SPRINT Era James H. Horner, MD, Symposium: **SPRINT Ahead – An Update in Hypertension September 22, 2023** William C. Cushman, MD, FAHA, FACP Medical Director and Professor, Department of Preventive Medicine, and Professor, Medicine and Physiology University of Tennessee Health Science Center Memphis, TN

Presenter Disclosure Information William C. Cushman, MD

FINANCIAL DISCLOSURE:

- Institutional grants:
- George Medicines
- ReCor Medical
- NIH



Office BP: Auscultatory Method

Mercury

Aneroid





Korotkoff 1905; Shevchenko 1996; Geddes LA. 1991; Beevers 2011

Office BP: Oscillometric Method



Cuff pressure at point of maximal oscillations is used to estimate BP

Marey 1876; Geddes LA. 1991

Sphygmomanometer options

- Mercury manometer:
 - banned in many clinical settings
 - Introduces observer error without frequent retraining
- "Manual" aneroid device:
 - needs frequent (every 6-12 months) calibration or assume it is inaccurate.
 - Introduces other observer errors.
- Automated (oscillometric) method
 - Best option to minimize observer errors
 - Best if fully automated device (push button and leave patient undisturbed)
- **Cuffless BP devices:** may be available in near future

Where To Look for validated devices for office or home

- Most devices sold on the market have not been rigorously validated.
- American Medical Association Validated Device List (VDL): Validatebp.org
- Alternative: Stridebp.org

Accurate Measurement of BP in the Office

COR	LOE	Recommendation for Accurate Measurement of BP in the Office
I	C-EO	For diagnosis and management of high BP, proper methods are recommended for accurate measurement and documentation of BP.

I would have said the LOE is "A", based on proper technique used in the epidemiologic studies and the major HTN outcome trials defining BP levels to determine risk, treatment thresholds, and BP goals.





International Consensus on Standardized Clinic Blood Pressure Measurement – A Call to Action

THE AMERICAN JOURNAL of MEDICINE ®

Published online January 2023

Routine Office BP versus Automated Office BP (mm Hg)

Study	Ν	Routine Office BP	Automated Office BP	$\Delta \mathbf{BP}$
Graves	104	152/84	136/79	16/5
Beckett	481	151/83	140/80	11/3
Myers-16	309	153/87	132/75	21/12
Myers-18	254	150/89	133/80	17/9
Myers-19	303	150/81	133/74	17/7
Mean		151/85	135/78	16/7

BP Measurement: of Paramount Importance!

- Patient seated with back supported and arm bared and supported at heart level.
- Patient should refrain from smoking or ingesting caffeine for 30 minutes prior to measurement.
- Measurement should begin after 5 minutes of rest (patient should not talk and not be spoken to).
- Use appropriate cuff size and validated equipment.
 - > About $\frac{1}{2}$ of U.S adults need a large adult cuff.
- Both SBP and DBP should be recorded. Check both arms on first visit: if >15 mm Hg different use higher arm.
- ≥2 readings: averaged or use median of 3 readings. 30-60sec between readings.
- Most practical way to do this: <u>fully automated oscillometric manometer</u>, preset to wait 5 minutes and take/average 3 readings (sometimes referred to as AOBP).



Best Proven Nonpharmacological Interventions for Prevention and Treatment of Hypertension*

	Nonpharmacologi-cal	Dose	Approximate Impact on SBP		
	Intervention		Hypertension	Normotension	
Weight loss	Weight/body fat	Best goal is ideal body weight, but aim for at least a 1-kg reduction in body weight for most adults who are overweight. Expect about 1 mm Hg for every 1- kg reduction in body weight.	-5 mm Hg	-2/3 mm Hg	
Healthy diet	DASH dietary pattern	Consume a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with reduced content of saturated and total fat.	-11 mm Hg	-3 mm Hg	
Reduced intake of dietary sodium	Dietary sodium	Optimal goal is <1500 mg/d, but aim for at least a 1000-mg/d reduction in most adults.	-5/6 mm Hg	-2/3 mm Hg	
Enhanced intake of dietary potassium	Dietary potassium	Aim for 3500–5000 mg/d, preferably by consumption of a diet rich in potassium.	-4/5 mm Hg	-2 mm Hg	
	Type, dose, *Type, dose, DASH indicat Resources: Your	and expected impact on BP in adults with a normal BP and with hyper es Dietary Approaches to Stop Hypertension; and SBP, systolic blood p Guide to Lowering Your Blood Pressure With DASH—How Do I Make	tension. pressure. the DASH?	American	



Available at: <u>https://www.nhlbi.nih.gov/health/resources/heart/hbp-dash-how-to</u>. Top 10 Dash Diet Tips. Available at: <u>http://dashdiet.org/dash_diet_tips.asp</u>



Best Proven Nonpharmacological Interventions for Prevention and Treatment of Hypertension* (cont.)

	Nonpharmacological	Dose	Approximate Impact on SBP		
	Intervention		Hypertension	Normotension	
Physical activity	Aerobic	● 90–150 min/wk	-5/8 mm Hg	-2/4 mm Hg	
		• 65%–75% heart rate reserve			
	Dynamic resistance	● 90–150 min/wk	-4 mm Hg	-2 mm Hg	
		• 50%–80% 1 rep maximum			
		• 6 exercises, 3 sets/exercise, 10			
		repetitions/set			
	Isometric resistance	• 4 × 2 min (hand grip), 1 min rest between	-5 mm Hg	-4 mm Hg	
		exercises, 30%–40% maximum voluntary			
		contraction, 3 sessions/wk			
		• 8–10 wk			
Moderation in	Alcohol consumption	In individuals who drink alcohol, reduce	-4 mm Hg	-3 mm	
alcohol intake		alcohol† to:			
		 Men: ≤2 drinks daily 			
		● Women: ≤1 drink daily			

*Type, dose, and expected impact on BP in adults with a normal BP and with hypertension.

†In the United States, one "standard" drink contains roughly 14 g of pure alcohol, which is typically found in 12 oz of regular beer (usually about 5%

alcohol), 5 oz of wine (usually about 12%

AMERICAN COLLEGE of CARDIOLOGY alcohol), and 1.5 oz of distilled spirits (usually about 40% alcohol).



Antihypertensive Drug Classes Currently used for Management of HTN

- Diuretics:
 - Thiazide-type
 - Loop
 - K-sparing
- Renin angiotensin system blockers:
 - Angiotensin converting-enzyme (ACE) inhibitors
 - Angiotensin receptor blockers (ARBs)
 - Direct renin inhibitors (DRIs)
- Calcium channel blockers (CCBs)

- Beta-blockers (BBs)
- Alpha-beta blockers
- Alpha₁-blockers
- Central alpha agonists
- Direct arterial vasodilators:
 - hydralazine
 - minoxidil

Best outcome data in HTN trials

Initial Choices of Medications



* Recommended for CKD Combining ACEI with ARB discouraged

National Heart

DIARFTES AND DIGEST

lational Institute on Add



SPRINT BP Intervention

- BP monitored monthly for 3 months and every 3 months thereafter (additional visits could be scheduled)
- Lifestyle background therapy recommended for all
- Antihypertensive medication titration decisions based on seated visit BP with fully automated BP manometer, using a structured stepped-care approach
- Classes with the best CVD outcomes in trials given priority
 - <u>Chlorthalidone</u> encouraged as thiazide-type diuretic
 - <u>Amlodipine</u> encouraged as CCB
- Periodic assessment for orthostatic hypotension and related symptoms

Cushman, et al. Hypertension 2022; 79:2071-2080





Chlorthalidone 25 mg vs HCTZ 50 mg: Change in 24-Hour Mean Systolic Blood Pressure



Start Here: begin with 2-3 drug therapy^{*} using a thiazide-type diuretic^{**}, and/or an ACEI or ARB (but not both) and/or a CCB

Intensive Group Algorithm Goal <120 mm Hg



ALLHAT

Cumulative Percent Controlled (BP <140/90 mm Hg) at Five Years



Derived from Cushman et al. J Clin Hypertens. 2002;4:393-404.

Systolic BP During Follow-up







DIABETES AND DIGESTIV

IND KIDNEY DISEASES

Antihypertensive Drug Classes in SPRINT



(10.1161/HYPERTENSIONAHA.121.17233)

© 2022 American Heart Association, Inc.

What were the unique antihypertensive medication combinations used by participants of the Systolic Blood Pressure Intervention Trial (SPRINT)?





Catherine G. Derington. Hypertension. Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial, Volume: 80, Issue: 3, Pages: 590-597, DOI: (10.1161/HYPERTENSIONAHA.122.20373)

© 2022 American Heart Association, Inc.

Systolic Distribution by Treatment Group

Most Recent Visit Per Participant



All Intensive All Standard





Systolic Blood Pressure Distribution in SPRINT



(10.1161/HYPERTENSIONAHA.121.17233)

© 2022 American Heart Association, Inc.

Management of Side Effects

- In SPRINT (with SPRINT medications) adverse effects were similar in both groups.
- Orthostatic hypotension was LESS common in intensive group
- Some AEs (AKI, hypotension, electrolyte disturbances) were more common in intensive group, but <2% more and usually reversible and easy to manage.
- No increase in falls or fractures.
- Older participants had more AEs, but no difference between randomized groups.

Primary Outcome



(Average Home SBP)



ESC CONGRESS (

Hot Line presentation

www.escardio.org/ESC2015

Improvement in BP in Black Patients Uncontrolled with Diuretic+CCB

2X2 factorial design (n=98): amiloride (10 mg/d) spironolactone (25 mg/d) combination of both drugs placebo



Drugs to Consider Adding to Initial 2-3 Drug Combinations

- spironolactone or amiloride: especially if K⁺ low or 1° aldosteronism.
- alpha blocker: especially if LUTS
- alternative CCB: avoid combining non-DHP c BB
- beta-blocker: safe to combine (except with non-DHP CCB) but does not add much efficacy to RAS blocker.
- vasodilator: hydralazine or minoxidil
- alpha-beta blocker: labetalol or carvedilol
- central agonist: most side effects frequency

Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension



Ş

Gianfranco Parati. Hypertension. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension, Volume: 77, Issue: 2, Pages: 692-705, DOI: (10.1161/HYPERTENSIONAHA.120.15781)

Relative reduction in BP: SPC therapy vs FEC therapy

Α											
Study	Tatal	Maan	SPC	Tatal	Maan	FEC	Mean	MD	05% 01	Weight	Weight
Study	Total	mean	501	otai	Mean	30	Difference	MD	95% CI	(lixed) (random
Week 4 McLay 2000	25	-16.50	3 6000	25	-15 10	3 7000	-	-1.40	[-3 42:0 62]	47.8%	24.5%
Nedogoda 2017	74	-19.80	9.4600	70	-19.00	11.7100		-0.80	[-4.29; 2.69]	16.1%	21.8%
Tanaka 2016	26	-4.50	16.0000	23	-13.40	16.1500	•	- 8.90	[-0.12; 17.92]	2.4%	11.3%
Mazza 2017	92	-11.60	10.7100	92	-6.90	8.5000		-4.70	[-7.49; -1.91]	25.1%	23.2%
Erdogan 2016	48	-9.50	10.3800	47	-6.90	13.1400		-2.60	[-7.37; 2.17]	8.6%	19.1%
Fixed effect mode	I 265			257			\diamond	-1.99	[-3.39; -0.59]	100.0%	-
Random effects m Heterogeneity: $l^2 =$	iodel 60%, τ ²	= 16.19	86, <i>p</i> = 0.0	4			\sim	-1.10	[-5.13; 2.93]	-	100.0%
Wook 8											
Tanaka 2016	26	-7.30	16.0000	23	-9.60	16.1500		2.30	[-6.72: 11.32]	2.2%	13.4%
Nedogoda 2017	74	-20.70	10.3200	70	-23.60	11.7100		2.90	[-0.71; 6.51]	51.1%	45.7%
Erdogan 2016	48	-14.20	9.8000	47	-12.00	10.3100		-2.20	[-6.25; 1.85]	40.7%	40.9%
Fixed effect mode	I 148			140			\$	0.77	[-1.81; 3.36]	100.0%	-
Random effects m	odel	- 1 019	6 0 - 0 17				\diamond	0.73	[-2.87; 4.34]	-	100.0%
neterogeneity: /* =	40 %, 1	- 4.010	0, p = 0.17								
Week 12 Bricout-Hennel 201	8 77	-20.00	9 7500	77	-11 00	10 6000		-9.00	[-12 22: -5 78]	29.0%	25.8%
Marazzi 2016	154	-19 47	14 2600	152	-14 40	14 2600		-5.00	[-8 27: -1 87]	29.4%	25.0%
Nedogoda 2017	74	-21.50	11,7000	70	-20.00	12,9000		-1.50	[-5.53: 2.53]	18.5%	23.5%
Visco 2017	26	-11.84	3.8600	13	-11.84	6.0600		0.00	[-3.61; 3.61]	23.0%	24.7%
Eived offect med-	1 224			210			~	4 90	L6 10: 0 651	100.0%	
Pixed effect mode	i 331			312			\sim	-4.38	[-0.12; -2.65]	100.0%	100.0%
riolarogeneny, r		- 12100	, p - 0.0			Fa	I I I I I 15 -10 -5 0 5 10 vors SPC Favors	T 15 FEC			
в											
			SPC			FEC	Mean			Weight \	Neight
Study	Total	Mean	SD1	Total	Mean	SD	Difference	MD	95% CI	(fixed) (r	andom)
Week 4							1				
McLay 2000	25	-10.30	2.4000	25	-10.20	2.4000	-	-0.10	[-1.43; 1.23]	44.3%	29.6%
Nedogoda 2017	74	-14.60	7.7400	70	-14.70	9.2000	-+	0.10	[-2.68; 2.88]	10.1%	24.0%
Tanaka 2016	26	-4.60	9.2400	23	-8.40	7.1000		- 3.80	[-0.79; 8.39]	3.7%	17.0%
Mazza 2017	92	-7.00	4.0900	92	-3.50	5.3000	•	-3.50	[-4.87; -2.13]	41.9%	29.4%
Fixed effect mode	217			210			\diamond	-1.36	[-2.24; -0.47]	100.0%	-
Random effects m Heterogeneity: $I^2 =$	10del 84%, τ	² = 6.306	62, <i>p</i> < 0.01					-0.39	[-3.16; 2.38]	-	100.0%
Week 8											
Tanaka 2016	26	-4.60	9.2400	23	-7.30	9.0500		- 2.70	[-2.43: 7.83]	22.8%	23.7%
Nedogoda 2017	74	-16.00	7.7400	70	-17.10	9.2000	-	1.10	[-1.68; 3.88]	77.2%	76.3%
Fixed effect mode	1 100			93				1.46	[-0.98: 3.91]	100.0%	_
Random effects m Heterogeneity: <i>I</i> ² =	odel 0%, τ ²	= 0.1615	5, <i>p</i> = 0.59				6	1.48	[-1.05; 4.01]	-	100.0%
Week 12	o ==	15.05	0.0465		10.05	1 0005	-	0.00		00.45	00.07
Bricout-Hennel 201	8 77	-15.00	3.9400	77	-12.00	4.2000	-	-3.00	[-4.29; -1.71]	30.1%	28.9%
Marazzi 2016	154	-9.45	5.9500	152	-8.27	5.9500	-	-1.18	[-2.51; 0.15]	28.0%	28.1%
Negogoga 2017	/4	-15.30	7.8000	70	-14.80	9.0000		-0.50	[-3.26; 2.26]	0.0%	12.3%
Visco 2017	00	-12 10	1 0700	10	-1/2 /3*	1 7 400					1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1
Visco 2017	26	-13.12	1.8700	13	-12.21	1.7400	-	-0.91	[-2.10; 0.28]	35.3%	30.6%
Visco 2017 Fixed effect mode	26 331	-13.12	1.8700	13 312	-12.21	1.7400	*	-0.91 -1.59	[-2.10; 0.28]	100.0%	30.6%

0

Favors FEC

Favors SPC

SPC: single-pill combination FEC: free-equivalent combination

DBP

SBP



Gianfranco Parati. Hypertension. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension, Volume: 77, Issue: 2, Pages: 692-705, DOI: (10.1161/HYPERTENSIONAHA.120.15781)

Heterogeneity: $I^2 = 56\%$, $\tau^2 = 0.7200$, p = 0.08

Proportion of studies demonstrating differences in adherence, persistence, blood pressure (BP) target achievement, and BP reductions in patients receiving single-pill combination (SPC) therapy or free-equivalent combination (FEC) therapy.



- Similar between both SPC and FEC therapy
- Significant improvement with FEC therapy



Gianfranco Parati. Hypertension. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension, Volume: 77, Issue: 2, Pages: 692-705, DOI: (10.1161/HYPERTENSIONAHA.120.15781)

© 2020 American Heart Association, Inc.

Conclusions

- Measure BP accurately in clinic and at home.
- Encourage lifestyle changes for prevention or treatment of HTN.
- Start with antihypertensive classes alone or in combination with the best cardiovascular outcome data.
- Act rapidly: titrate medications at least monthly, intensify until at goal or decision made to stop intensifying – most patients need at least 3 medications.
- Expect some side effects when treating HTN appropriately most can be managed effectively.
- Consider single-pill combinations (SPCs) frequently to improve adherence and BP control.

Thank you!

Clinic, Home, and Ambulatory BP Measurements

Muntner, P. et al. Blood Pressure Assessment in Adults in Clinical Practice and Clinic-Based Research. J Am Coll Cardiol. 2019;73(3):317–35.

Clinic Measurements	Home BP Monitoring	Ambulatory BP Monitoring		
	Description			
 BP measured in a medical setting Patient should be seated, resting quietly with their back supported and feet flat on the floor 	 BP measured while seated at home, resting quietly with back supported and feet flat on the floor BP readings obtained in the morning and evening 	 BP measured during routine activities 48 to 72 readings obtained over 24 hours 		
	Strengths			
 Associated with cardiovascular outcomes Only method that has been used to guide treatment in large outcome trials 	 Strong association with cardiovascular outcomes Detects white coat and masked hypertension 	 Strong association with cardiovascular outcomes Detects white coat and masked hypertension BP measured at work and at night (i.e., during sleep) 		
	Weaknesses			
 Less precise as only 1 or 2 BP measurements typically obtained Many factors affect the accuracy of readings Requires training and frequent re-training of staff 	 Patients may not correctly measure and report their BP Requires patient training and re-training Many home devices are not validated 	 Not tolerated by some patients Equipment is not widely available Requires two clinic visits: to set up and return the device 		

FIGURE 1 BP Phenotypes Defined by Combinations of Clinic and Out-of-Clinic BP



Out-of-Office and Self-Monitoring of BP

COR	LOE	Recommendation for Out-of-Office and Self-Monitoring of BP
I	Asr	Out-of-office BP measurements are recommended to confirm the diagnosis of hypertension and for titration of BP-lowering medication, in conjunction with telehealth counseling or clinical interventions.

SR indicates systematic review.

However:

- 1. Some recent studies and meta-analysis suggest people with WCH have elevated CVD risk.
- 2. Those with WCH were never excluded from major treatment trials and we did not know who they were.
- 3. People with masked HTN were never included in trials.

Therefore, I recommend using OOO BPs to "inform" diagnosis and treatment decisions. 2020 VA/DoD and 2021 KDIGO HTN guidelines reflect this.



2017 ACC/AHA Hypertension Guidelines

